Rubius Therapeutics, Inc.
RUBYDelisted Mar 28, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001709401
Rubius Therapeutics, Inc. was delisted on Mar 28, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 42 institutions reported holding it in 13F filings for Q4 2022, worth $11.2M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Rubius Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Rubius Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Appelhans Dannielle | CEO and President | 0 | Feb 27, 2023 | 0 |
| Cagnoni Pablo J | Director | 66,082 | Feb 1, 2023 | 0 |
| Turka Laurence A. | Chief Scientific Officer | 18,391 | Jan 31, 2023 | 0 |
| Schaffert Susanne | Director | – | Aug 1, 2022 | 0 |
| Afeyan Noubar | Director, 10% Owner | – | May 13, 2022 | 0 |
| Epstein David R | Director | 4,720,012 | May 13, 2022 | 0 |
| Rosenblatt Michael | Director | – | May 13, 2022 | 0 |
| Cuss Francis M | Director | – | May 13, 2022 | 0 |
| Sohn Catherine A. | Director | – | May 13, 2022 | 0 |
| Holles Natalie C. | Director | – | May 13, 2022 | 0 |
| Symonds Jonathan | Director | – | May 13, 2022 | 0 |
| Prener Anne | Director | – | May 13, 2022 | 0 |
| Carmona Jose | Chief Financial Officer | – | Feb 1, 2022 | 0 |
| Keson-Brookes Maiken | CLO & Corp. Secretary | 5,343 | Feb 1, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 (view filing)6:08 PM ET | Feb 24 | 3 days | Appelhans DannielleCEO and President | SSale | −10.4K | $0.1274 | −$1.32K | −100.0%0 after | |
| Feb 1, 2023 (view filing)9:41 PM ET | Feb 1 | Same day | Cagnoni Pablo JDirector | SSale | −8.45K | $0.25 | −$2.11K | −11.3%66.1K after | |
| Feb 1, 2023 (view filing)9:40 PM ET | Feb 1 | Same day | Appelhans DannielleCEO and President | SSale | −3.88K | $0.25 | −$969.5 | −27.2%10.4K after | |
| Jan 31, 2023 (view filing)9:51 PM ET | Jan 31 | Same day | Cagnoni Pablo JDirector | SSale | −7.24K | $0.241 | −$1.74K | −8.9%74.5K after | |
| Jan 31, 2023 (view filing)9:50 PM ET | Jan 31 | Same day | Turka Laurence A.Chief Scientific Officer | SSale | −2.59K | $0.24 | −$622.32 | −12.4%18.4K after | |
| Aug 12, 2022 (view filing) | Aug 10 | 2 days | Appelhans DannielleChief Operating Officer | SSale | −5.74K | $0.80 | −$4.59K | −45.9%6.76K after | |
| Apr 22, 2022 (view filing) | Apr 21 | 1 day | Epstein David RDirector | PPurchase | +30.0K | $1.44 | +$43.2K | +0.6%4.72M after | |
| Feb 1, 2022 (view filing) | Feb 1 | Same day | Cagnoni Pablo JCEO and President | SSale | −6.73K | $6.57 | −$44.2K | −15.9%35.5K after | |
| Feb 1, 2022 (view filing) | Feb 1 | Same day | Keson-Brookes MaikenCLO & Corp. Secretary | SSale | −2.73K | $6.57 | −$17.9K | −33.8%5.34K after | |
| Feb 1, 2022 (view filing) | Feb 1 | Same day | Turka Laurence A.Chief Scientific Officer | SSale | −2.52K | $6.57 | −$16.5K | −33.8%4.92K after |